Pre-eclampsia (PE) is a significant health concern for pregnant women, with a prevalence of 2-5% worldwide and as high as 8-12% in some African countries. PE can lead to serious complications, including organ damage and fetal growth restriction, and is a leading cause of maternal and perinatal morbidity and mortality. Learn more about this condition from our collection of UOG Journal articles.
In recognition of Pre-eclampsia Awareness month in May, ISUOG has curated a valuable collection of UOG articles from our esteemed community of expert clinicians. These resources cover a range of topics related to pre-eclampsia, including effective screening methods, optimal strategies for managing hypertension and pre-eclampsia towards the end of pregnancy and accurate risk assessment for pre-eclampsia. We encourage healthcare professionals to explore these resources and stay up-to-date with the latest developments in pre-eclampsia research and management.
UOG Journal Collection: Pre-eclampsia
Routine first-trimester pre-eclampsia screening and risk of preterm birth
Preterm birth (PTB) is a major public health problem worldwide. It can occur spontaneously or be medically indicated for obstetric complications, such as pre-eclampsia (PE) or fetal growth restriction. The main objective of this study was to investigate whether there is a shared uteroplacental etiology in the first trimester of pregnancy across PTB subtypes.
Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China
An evaluation among a Chinese population on the performance of a screening strategy for preterm pre-eclampsia (PE) using The Fetal Medicine Foundation (FMF)'s competing-risks model and to explore its clinical applicability in mainland China.
Comparison of ophthalmic artery Doppler with PlGF and sFlt-1/PlGF ratio at 35–37 weeks' gestation in prediction of imminent pre-eclampsia
A comparison on the predictive performance for delivery with pre-eclampsia (PE) at < 3 weeks and at any stage after assessment at 35 + 0 to 36 + 6 weeks' gestation of serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1)/PlGF ratio with that of a competing-risks model utilizing maternal risk factors, mean arterial pressure (MAP) and ophthalmic artery peak systolic velocity (PSV) ratio.
Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction
A summary of the existing knowledge, examining the performance of maternal PlGF, sFlt-1 and the sFlt-1/PlGF ratio for screening PE, predicting development of PE in the short term, diagnosing PE, monitoring established PE and predicting other placenta-related disorders in singleton pregnancy, as well as discussion on the performance of PlGF and the sFlt-1/PlGF ratio for predicting PE in twin pregnancy.
ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine artery pulsatility index trajectories in pregnancy
The mechanism by which aspirin prevents pre-eclampsia is poorly understood, and its effects on biomarkers throughout pregnancy are unknown. The aim of this study was to investigate the effects of aspirin on mean arterial pressure (MAP) and mean uterine artery pulsatility index (UtPI) using repeated measures from women at increased risk of preterm pre-eclampsia.
ISUOG Practice Guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia
The aim of these Guidelines is to review the latest evidence and, when possible, provide evidence-based recommendations regarding the role of ultrasound in screening and follow-up of PE.
Ask the Expert
Prof. Kypros Nicolaides and Prof. Liona Poon answer the questions surrounding pre-eclampsia that matter most to our community's patients in a compelling series of videos. Click here to access.
Read, Watch, Learn
Get insight from our Expert Voices resource page on pre-eclampsia, including papers and lectures from Prof. Kypros Nicolaides, by clicking here.